Chemotherapy for metastatic bladder cancer

Clinical Oncology

Volumn 17, Issue 7, 2005, Pages 514-523

  Roberts, J Trevor ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antineoplastic agents; Bladder neoplasms; Metastasis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; RETINOBLASTOMA PROTEIN; VASCULOTROPIN; VINBLASTINE;

ADVANCED CANCER; ALOPECIA; BLADDER CANCER; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CYTOPENIA; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LONG TERM CARE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEPHROSTOMY; NEPHROTOXICITY; NEUROTOXICITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

EID: 25144464890     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.07.007     Document Type: Article

References (100)

1. A. Yagoda Phase II trials in patients with urothelial tumours: Memorial Sloan-Kettering Centre Cancer Chemother Pharmacol 11 suppl 1983 9-12
2. H.W. Herr cis-Diamminedichloroplatinum II as a therapeutic agent in the treatment of advanced bladder cancer J Urol 123 1980 853-857
3. P.C. Peters M.R. O'Neill cis-Diamminodichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma J Urol 123 1980 375-377
4. C. Merrin Treatment of advanced bladder cancer with cis-diamminodichloroplatinum II: A pilot study J Urol 119 1978 493-495
5. M.S. Soloway M. Ikard K. Ford cis-Diamminodichloroplatinum (II) in locally advanced and metastatic urothelial cancer Cancer 47 1981 476-480
6. M. DeLena V. Lorrusso U. Iacobellis F. Marzullo A. Crammarossa cis-Diaminochloplatinum activity in bidimensionally measurable metastatic lesions of bladder carcinoma Tumori 70 1984 85-88
7. R.T.D. Oliver E.S. Newlands E. Wiltshaw J.S. Malpas A phase II study of cis-platinum in patients with recurrent bladder carcinoma Br J Urol 53 1981 444-447
8. A.M. Russof R.W. Talley R.L. Stephens et al. Phase II evaluation of cis-dichlorodiammineplatinum in advanced malignancy of the genitourinary and gynaecological organs: A Southwest Oncology Group study Cancer Treat Rep 63 1979 1557-1564
9. S.L. Fagg P. Dawson-Edwards M.A. Hughes T.N. Latief E.B. Rolfe J.W.L. Fielding cis-Diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer Br J Urol 56 1984 296-300
10. D. Raghavan B. Pearson P. Duval et al. Initial intravenous cis-platinum: improved management for high-risk metastatic bladder cancer J Urol 133 1985 399-402
11. P.J. Loehrer L.H. Einhorn P.J. Elson et al. A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study J Clin Oncol 10 1992 1066-1073
12. J.D. Khandekar P.J. Elson W.D. DeWys R.E. Slayton D.T. Harris Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract J Clin Oncol 3 1985 539-545
13. M.S. Soloway A. Einstein M.P. Corder W. Bonney G.R. Prout J. Coombes A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer Cancer 52 1983 767-772
14. B.L. Hillcoat D. Raghanan J. Matthews et al. A randomised trial of cisplatin versus cisplatin plus methotrexate in advanced carcinoma of the urinary tract J Clin Oncol 7 1989 706-709
15. M. Troner R. Birch G.A. Omura S. Williams Phase II comparison of cisplatin alone versus cisplatin, doxorubicin, and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group Trial J Urol 137 1987 660-662
16. M. Al-Sarraf J. Frank J.A. Smith Jr. et al. Phase II trial of cyclophosphamide, doxorubicin and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study Cancer Treat Rep 69 1985 189-194
17. N. Mottet-Auselo F. Bons-Rosset P. Costa J.F. Louis H. Navratil Carboplatin and urothelial tumours Oncology 50 suppl 2 1993 28-36
18. N.K. Rabbe S.D. Fosså G. Paro Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder Br J Urol 64 1989 604-607
19. A.G. Turner W.F. Hendry G.B. Williams H.J.G. Bloom The treatment of advanced bladder cancer with methotrexate Br J Urol 49 1977 673-678
20. R.R. Hall H.J.G. Bloom J.R. Freeman A. Nawrocki D.M. Wallace Methotrexate treatment for advanced bladder cancer Br J Cancer 35 1977 40-51
21. N.H. Gad-el-Mawla R. Hamsa J. Cairns T. Anderson J.L. Ziegler Phase II analysis of methotrexate in carcinoma of the bilharzial bladder Cancer Treat Rep 62 1978 1075-1076
22. R.B. Natale A. Yagoda R.C. Watson W.F. Whitmore M. Blumenrich D.W. Braun Methotrexate: An active drug in bladder cancer Cancer 47 1981 1246-1250
23. A.G. Turner Methotrexate for advanced bladder cancer Cancer Treat Rep 62 1981 183-186
24. M. Pavone-Macaluso EORTC Gentourinary Cooperative Group A Single drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin Eur Urol 2 1976 138-141
25. R.M. O'Brian L.H. Baker J.E. Gottlieb et al. Dose-response evaluation of Adriamycin in human neoplasia Cancer 39 1977 1940-1948
26. A. Yagoda R.C. Watson W.F. Whitmore H. Grabstadt M.F. Middleman H.I. Krakoff Adriamycin in advanced urinary tract cancer: Experience in 42 patients and review of the literature Cancer 39 1977 279-285
27. E.W. Knight E.M. Pagand R.G. Hahn J. Horton Comparison of 5-FU and doxorubicin in the treatment of bladder cancer Cancer Treat Rep 67 1983 514-515
28. R. Gagliano H. Levin M.N. El-Bolkainy et al. Adriamycin versus Adriamycin plus cis-dichlorodiammineplatinum (II) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group study Am J Clin Oncol 6 1983 215-218
29. M.S. Blumenreich A. Yagoda R.B. Natale R.C. Watson Phase II trial of vinblastine sulfate for metastatic urothelial tract tumours Cancer 50 1982 435-438
30. B.J. Roth R. Dreicer L.H. Einhorn et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 12 1994 2264-2270
31. D. Papamichael C.J. Gallagher R.T. Oliver et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic carcinoma of the bladder and ureter Br J Cancer 75 1997 606-607
32. R. Dreicer D.M. Gustin W.A. See R.D. Williams Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy J Urol 156 1996 1606-1608
33. J.A. McCaffrey S. Hilton M. Mazumdar et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma J Clin Oncol 15 1997 1853-1857
34. V. Lorusso C.F. Pollera M. Antimi et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer Eur J Cancer 34 1998 1208-1212
35. V. Gebbia A. Testa N. Borsellino et al. Single agent 2′,2′-difluorodeocycitadine in the treatment of metastatic urothelial carcinoma: A phase II study Clin Ther 150 1999 11-15
36. M.J. Moore I.F. Tannock D.S. Ernst et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 1997 3441-3445
37. W.M. Stadler T. Kuzel B. Roth et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 1997 3394-3398
38. G.J. Peters A.M. Bergman V.W. Ruiz van Haperen G. Veerman C.M. Kuiper B.J. Braakhuis Interaction between cisplatin and gemcitabine in vitro and in vivo Semin Oncol 22 4 suppl 11 1995 72-79
39. H. von der Maase L. Anderson L. Crino et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional carcinoma of the urothelium: A phase II clinical trial Ann Oncol 10 1999 1461-1465
40. M.J. Moore E.W. Winquist N. Murray et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2867-2881
41. D. Kaufman D. Raghavan M. Carducci et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921-1927
42. G. Stoter T.A.W. Splinter J.A. Child et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder J Urol 137 1987 663-667
43. R.T.D. Oliver Chemotherapy of invasive carcinoma of the bladder Aust N Z J Surg 55 1985 249-252
44. R.T.D. Oliver H.K. Kwok W.J. Highman J. Waxman Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer Br J Urol 58 1986 31-35
45. J. Carmichael M.A. Cornbleet F.H. MacDougal et al. Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract Br J Urol 57 1985 299-302
46. W.G. Harker F.J. Meyers F.S. Freiha et al. Cisplatin, methotrexate and vinblastine (CMV): An effective treatment for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study J Clin Oncol 3 1985 1463-1470
47. C.N. Sternberg A. Yagoda H.W. Herr et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium J Urol 133 1985 403-407
48. J. Waxman Chemotherapy for bladder cancer. Is there new hope? Br J Urol 65 1990 1-6
49. C.N. Sternberg A. Yagoda H.W. Herr et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the urothelium J Urol 139 1988 461-469
50. C.N. Sternberg A. Yagoda H. Scher et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse Cancer 64 1989 2448-2458
51. I. Tannock M. Gospodarawicz J. Connolly M. Jewett M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience J Urol 142 1989 289-292
52. M. Igwa T. Ohkuchi M. Ueda K. Okada T. Usui Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer J Urol 144 1990 662-665
53. A. Boutan-Laroze M. Mahjoubi J.P. Droz et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder Eur J Cancer 27 1991 1690-1694
54. C.J. Logothetis F.H. Dexeus L. Finn R.J. Amato A.G. Ayala R.G. Kilbourn A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours J Clin Oncol 8 1990 1050-1055
55. J. Bellmunt A. Ribas N. Eres et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 1997 1966-1972
56. R. Dreicer J. Manola B.J. Roth et al. Phase III trial of methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Cancer 100 2004 1639-1645
57. C.N. Sternberg P.H. de Mulder J.H. Schornagel et al. Randomised phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human colony stimulating factor for the initial treatment of advanced malignant urothelial tract tumours: European Organization for Research and Treatment of Cancer Protocol no. 30924 J Clin Oncol 19 2001 2638-2646
58. H. von der Maase S.W. Hansen J.T. Roberts et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer; results of a large, randomised, multinational, multicentre phase III study J Clin Oncol 18 2000 2448-2458
59. J. Klocker J. Pont J. Schumer J. Prüger H. Kienzer Carboplatin, methotrexate and vinblastine (Carbo-MV) for advanced urothelial cancer: a phase II trial Am J Clin Oncol 14 1991 328-330
60. J. Waxman P. Abel J.N. Farah et al. New combination chemotherapy programme for bladder cancer Br J Urol 63 1989 68-71
61. J. Waxman C. Barton Carboplatin-based chemotherapy for bladder cancer Cancer Treat Rev 19 suppl C 1993 21-25
62. V. Lorusso A. Pagliarulo F.P. Selvaggi et al. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin) J Chemother 8 1996 154-158
63. R. Petrioli B. Frediani A. Manganelli et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomised phase II study Cancer 77 1996 344-351
64. G.D. Carteni L. Crucitta E. Martoni et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU) [abstract 1543] Proc Am Soc Clin Oncol 22 2003 384
65. G.M. Mead M. Russell P. Clark et al. A randomised trial comparing methotrexate and vinblastine with cisplatin methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council Study Br J Cancer 78 1998 1067-1075
66. A. Goldfarb A. Negro F. Coimbra et al. Methotrexate, vinblastine epipodophyllotoxins and cisplatin (M-VEC) for stage II-IV bladder cancer Proc Am Soc Clin Oncol 11 1992 210
67. R. Passalcqua G. Cocconi G. Macaluso et al. M-VAC versus the same combination using epirubicin at double dose in locally invasive bladder cancer: A prospective study Proc Am Soc Clin Oncol 11 1992 210
68. M. Kuroda T. Kotake H. Akaza et al. Efficacy of dose-intensified MEC (methotrexate, epirubicin chemotherapy for advanced urothelial carcinoma: A prospective randomised trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) Japanese Urological Cancer Research Group Jpn J Clin Oncol 28 1998 497-501
69. J.A. McCaffrey S. Hilton M. Mazumdar et al. Phase II randomised trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional cell carcinoma J Clin Oncol 15 1997 2449-2455
70. D.L. Trump P. Elson S. Madajewicz et al. Randomised phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group J Urol 144 1990 1119-1122
71. Smalley RV, Bartolucci AA, Hemstreet G, Hester M. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 1981;125:191-195.
72. S.B. Saxman K.J. Propert L.H. Einhorn et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A co-operative group study J Clin Oncol 15 1997 2564-2569
73. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomised trial comparing gemcitabine/cisplatin and methotrexate, vinblastine, doxorubicin and cisplatin in patients with locally advanced and/or metastatic bladder cancer. J Clin Oncol, in press.
74. P.M. Dodd A. McCaffrey H. Herr et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma J Clin Oncol 17 1999 2546-2552
75. H. Herr S.M. Donat D.F. Bajorin Post chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer J Urol 165 2001 811-814
76. P. Robinson H. von der Maase S. Bhalla et al. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Expert Rev Pharmacoecon Outcomes Res 2004 27-38
77. S.D. Fosså C. Sternberg H.I. Scher et al. Survival of patients with advanced urothelial cancer treated with cisplatin based chemotherapy Br J Cancer 74 1996 1655-1659
78. J. Bellmunt J. Albanell L. Paz-Ares et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin and gemcitabine Cancer 95 2002 751-757
79. W.M. Stadler A. Hayden H. von der Maase et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer Urol Oncol 7 2002 153-157
80. F.J. Myers J.M. Palmer F.S. Freyha et al. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: A Northern California Oncology Group study J Urol 134 1985 1118-1121
81. H.I. Scher A. Yagoda H.W. Herr et al. Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion J Urol 139 1988 470-474
82. J.D. Chester Gh Hall M. Forster A.S. Protheroe Systemic chemotherapy for patients with bladder cancer - current controversies and future directions Cancer Treat Rev 30 2004 343-358
83. S.A. Hussain D.D. Stocken P. Ridley et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer Br J Cancer 91 2004 844-849
84. B. Castagneto S. Zai D. Maraceno et al. Single agent gemcitabine in previously untreated elderly patients with advanced bladder cancer: response to treatment and correlation with the comprehensive geriatric assessment Oncology 67 2004 27-32
85. J. Bellmunt V. Guillem L. Paz-Arez et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional cell carcinoma of the urothelium J Clin Oncol 2000 3247-3255
86. A. Ardavanis D. Tryfonopoulos A. Alexopoulos C. Kandylis G. Lainakis G. Rigatos Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study Br J Cancer 92 2005 645-650
87. J. Li C. Yiannoutsos R. Ansari et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study J Clin Oncol 23 2005 1185-1191
88. D.S. Kaufman M.A. Carducci T.M. Kuzel et al. A multi-institution trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer Urol Oncol 22 2004 393-397
89. B.J. Gitlitz C. Baker Y. Chapman H.J. Allen et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Cancer 98 2003 1863-1869
90. M.L. Dunsford G.M. Mead A.C. Bateman T. Cook K. Tung Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma Ann Oncol 10 1999 943-947
91. H. von der Maase Pemetrexed in transitional cell carcinoma of the urothelium Oncology 18 13 suppl 8 2004 48-50
92. P.N. Lara Jr. F.L. Meyers L.Y. Law et al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma Cancer 100 2004 82-88
93. K. Turkolmez Y. Beduk S. Baldaci C. Gogus O. Gogus Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy Eur Urol 44 2003 682-686
94. S. Culine X. Rebillard F. Iborra et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: A pilot study Anticancer Res 23 2003 1903-1906
95. R.T. Bryan S.A. Hussain N.D. James J.A. Jankowski M.A. Wallace Molecular pathways in bladder cancer: Part 1 BJU Int 95 2005 485-490
96. R.T. Bryan S.A. Hussain N.D. James J.A. Jankowski M.A. Wallace Molecular pathways in bladder cancer: Part 1 BJU Int 95 2005 491-496
97. K.N. Qureshi T.R. Griffiths M.C. Robinson Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy Int J Radiat Oncol Biol Phys 51 2001 1234-1240
98. K.N. Qureshi T.R. Griffiths M.C. Robinson et al. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer Clin Cancer Res 5 1999 3500-3507
99. S.A. Hussain R. Ganesan L. Hiller et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder Oncol Rep 10 2003 571-576
100. P.W. Cooke N.D. James R. Ganesan A. Burton L.S. Young D.M. Wallace Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant radiotherapy BJU Int 85 2000 829-835